Bevacizumab (Avastin) Use In HHT
Hereditary hemorrhagic telangiectasia (HHT, also known as OslerWeber-Rendu Syndrome) is a condition that is characterized by focal proliferation of blood vessels (vascular malformations) in multiple organs. Two of the most commonly affected organs include the nose and gastrointestinal tract, which lead to chronic epistaxis (nose bleeds) and GI bleeding. 1 Bleeding in HHT patients leads to chronic anemia, potential high-output heart failure and an overall poor quality of life. In severe cases, HHT can lead to massive bleeding and death. Many HHT patients require multiple ENT procedures, upper and lower endoscopy procedures, recurrent blood transfusions and intravenous replacement of iron. Although these procedures provide temporary relief, they do not treat the underlying pathophysiology of the disease.